Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1632 1647
This examiner grants 38% of resolved cases
Matthew Curran Metcalf, in Tech Center 1600 and Art Unit 1622, has 8 resolved cases. The allowance rate is 37.5 percent, but the interview lift is a very high 71.4 percent. This 71.4 percent lift is extremely significant compared to the 37.5 percent baseline. The 37.5 percent allowance rate is low, but the 71.4 percent lift suggests that interviews are the most effective way to get a case allowed.
The median time to allowance is 1300 days. While the 37.5 percent allowance rate is challenging, the 71.4 percent interview lift is a powerful tool for applicants. Counsel should be prepared for a 1300 day timeline and should always request an interview. With only 8 resolved cases, the data is limited but clear on the value of interviews. The 1300 day pendency and 71.4 percent lift are the defining characteristics of prosecution with this examiner. Utilizing the 71.4 percent lift is essential for success.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18691666 | CELLULAR THERAPY TO SUPPRESS IMMUNE RESPONSE | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. |
| 18289049 | ASSESSING AND TREATING CANCER | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18685350 | COMPOSITIONS AND METHODS COMPRISING LIPID ASSOCIATED TRANSMEMBRANE DOMAINS | Non-Final OA | The Regents of the University of California |
| 18589384 | MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18518384 | OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF | Non-Final OA | Juno Therapeutics, Inc. |
| 18296711 | IMMUNO ONCOLOGY THERAPIES WITH IL-2 CONJUGATES | Non-Final OA | SANOFI |
| 18562108 | METHODS FOR THE TREATMENT OF OSTEOARTHRITIS | Non-Final OA | Novartis AG |
| 18292247 | COMPOSITIONS AND METHODS FOR ENHANCING CAR T CELL EFFICACY THROUGH THE ENGINEERED SECRETION OF C. PERFRINGENS NEURAMINIDASE | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18563037 | METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPY | Non-Final OA | Celgene Corporation |
| 18570257 | COMBINATION DOSAGE REGIME OF CD137 AND PD-L1 BINDING AGENTS | Non-Final OA | BioNTech SE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy